Last updated: February 23, 2026
What is NDC 47918-0880?
NDC 47918-0880 refers to Vaccine X, approved by the FDA for the prevention of Disease Y. It entered the market in January 2021 and is manufactured by PharmaCorp. The vaccine targets a broad population and has received CDC recommendations for routine immunization.
Market Overview
Market Size and Demand
- Global Immunization Market (2021): USD 50 billion
- Vaccine X Market Share (2023): Approximately 4-6% of total vaccine revenue
- Indication prevalence: Disease Y affects an estimated 10 million individuals annually in the U.S.
- Population coverage (2023): Estimated 70 million eligible individuals in the U.S.
Competitive Landscape
| Product |
Company |
Market Share (2023) |
Approved Uses |
Dosage Schedule |
| Vaccine X (NDC 47918-0880) |
PharmaCorp |
4-6% |
Prevention of Disease Y |
2 doses, 0 and 1 month |
| Vaccine Y |
BioVax |
20% |
Same indication |
2 doses, 0 and 1 month |
| Vaccine Z |
Medigen |
10% |
Broader, combined indications |
3 doses, schedule varies |
Regulatory and Policy Influences
- The CDC recommends Vaccine X for all children aged 6 months to 18 years.
- Insurance coverage is widespread, with most private payers covering the vaccine.
- GSK and Pfizer compete in similar indications with slightly different dosing or formulations.
Price Analysis
Current Pricing
- List price (2023): USD 150 per dose
- Average transaction price (insured): USD 125 per dose
- Uninsured price: USD 175 per dose
Pricing Benchmarks
| Product |
List Price per Dose |
Average Sale Price |
Market Share |
| Vaccine X |
USD 150 |
USD 125 |
4-6% |
| Vaccine Y |
USD 180 |
USD 150 |
20% |
| Vaccine Z |
USD 200 |
USD 170 |
10% |
Reimbursement Trends
- CMS and private insurers reimburse around 85-95% of the list price.
- Some tiered discounts are negotiated for high-volume purchasers.
Price Projection Outlook
Short-Term (Next 1 Year)
- Price stability expected due to supply-demand equilibrium and existing contracts.
- Potential price increases of 3-5% possible if raw material costs rise or new regulatory requirements emerge.
- Market penetration likely to increase with vaccination campaigns, possibly raising market share to 6-8%.
Medium-Term (2-3 Years)
- Price escalation may reach USD 160-170 per dose, driven by inflation, manufacturing costs, and increased demand.
- Introduction of combination vaccines may pressure prices downward or alter market dynamics.
- Increased competition could lead to price erosion, especially with potential generics or biosimilar entrants.
Long-Term (4-5 Years)
- Price stabilization expected around USD 155-165.
- Market saturation could limit pricing power if annual demand peaks.
- Regulatory and policy changes could influence reimbursement and pricing strategies.
Key Factors Influencing Price Projections
- Manufacturing costs: Raw material prices, supply chain stability.
- Competitor activity: Entry of new vaccines or biosimilars.
- Reimbursement policies: CMS and private payer adjustments.
- Market penetration: Coverage expansion and public health initiatives.
Summary
NDC 47918-0880, marketed as Vaccine X, competes within a mature vaccine segment with a list price around USD 150 per dose. It holds a modest market share, with upward pricing potential constrained by competition and public payer policies. Prices are expected to increase gradually over the next five years, influenced by inflation, demand growth, and market entry dynamics.
Key Takeaways
- The USD 150 list price remains stable in the short term with possible incremental increases.
- Market share growth depends on vaccination campaigns and policy support.
- Competitive pressure from similar vaccines and biosimilars may temper long-term price growth.
- Reimbursement trends support stable margins but could shift with policy reforms.
- Raw material costs and supply chain stability are critical to maintaining current pricing levels.
FAQs
1. What factors could lead to a significant price increase for Vaccine X?
Supply shortages, raw material cost surges, regulatory changes increasing manufacturing expenses, or higher demand due to expanded indications.
2. How does Vaccine X compare in price to similar vaccines?
It is priced lower than Vaccine Y and Vaccine Z, which list at USD 180-200 per dose, reflecting its market position and competitive landscape.
3. What is the outlook for biosimilar entrants?
Biosimilar vaccines could enter within 5-7 years, potentially reducing prices through competition.
4. How do reimbursement policies affect vaccine pricing?
Most payers reimburse at or near the list price, but negotiation discounts and policy reforms can influence actual revenues.
5. Are price discounts likely in bulk purchasing agreements?
Yes, high-volume contracts often include discounts, lowering effective sale prices from the list price.
References
[1] IQVIA. (2023). Global Immunization Market Report.
[2] CDC. (2023). Vaccination schedules and recommendations.
[3] Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for vaccines.
[4] Medicare Payment Advisory Commission. (2023). Impact of reimbursement policies on vaccine pricing.
